Fig 1.
Cell viability of ovarian cancer cell lines treated with Nutlin-3a.
All 15 cell lines were plated at a density of 1 × 103 cells per well in 96-well plates. After 24h, media was exchanged and cells were treated with incremental concentrations of Nutlin-3a (1 μM, 5 μM, 10 μM, 25 μM, 50 μM, and 70 μM). After 72h of Nutlin-3a treatment, cell viability was measured by WST assay and compared to untreated control.
Fig 2.
Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated in Table 1.
C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.
Table 1.
TP53 mutation status and Nutlin-3a sensitivity of ovarian cancer cell lines.
Fig 3.
Gene expression of p21, TP53, and MDM2 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated in Table 1.
(A) TP53. (B) p21. (C) MDM2.
Fig 4.
Cell death after Nutlin-3a exposure.
Apoptosis was evaluated after treating HOC-7 and A2780 with 4 μM and 5 μM Nutlin-3a at their corresponding IC50 or DMSO control, and staining with Annexin-V at 24 h. The number represents the percentage of early apoptotic cells in each condition.
Table 2.
List of genes significantly up-regulated in Nutlin-3a resistant cancer cell lines with wild-type TP53.